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annual rate of 3% in the base case analysis. We conducted 
sensitivity analyses to investigate how variation in overall 
survival with and without RT, RT demand, projected GDP 
growth rates, and operational and infrastructure costs per 
fraction impacted projections. 
Results:  In the base case “rapid” investment scenario, a 
total of 24,383,261 discounted life years are gained by 2035 
through scaling up radiotherapy capacity. This represents 
4,131,981 LYs in upper-middle, 11,006,360 LYs in lower-
middle, and 9,245,240 LYs in low-income countries. This 
results in a total of 124,389,936,346 USD discounted net 
monetary benefits accrued through productivity gains. 
Different investment scenarios and costing packages impact 
the rate of return.  
Conclusion: The health and economic benefits from 
improving access to radiotherapy capacity are projected to 
be substantial. Despite the capital costs associated with 
implementing radiotherapy infrastructure, the adoption of a 
long-term perspective demonstrates that in addition to the 
large health gains generated, the economic gains of 
radiotherapy investment are likely to offset programmatic 
costs. Scaling up radiotherapy capacity may be considered a 
cost-saving intervention, which may warrant priority within 
the health budgets of LMIC.  
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The structure and mechanics of tumour vasculature as well as 
oxygen consumption by the cancer determines the levels of 
tumour hypoxia.  Vascular structure is affected by 
remodeling that can be altered after agents inhibition of 
oncogenic signaling in the cancer cells. Inhibition of the RAS-
PI3K signalling  pathway leads to morphological changes 
resulting in increased perfusion and decreased vascular 
tortuosity. At the same time inhibition of the pathway also 
leads to decreased oxygen consumption. Together then the 
result of RAS-PI3K inhibition is decreased tumour hypoxia and 
increased tumour growth delay after radiation therapy.   
While decreased hypoxia during radiation therapy should 
increase efficacy, recurrence of tumours after therapy could 
be expected to require neoangiogenesis. Inhibition of 
angiogenesis using an antibody to notch ligand DLL4 led to 
superadditive reduction in tumour regrowth after radiation.  
However these studies cannot fully describe the events that 
might occur after fractionated radiation.  After fractionated 
radiation we find increased deposition of the potent 
angiogenic stimulator, FGF2 by recruited myeloid cells.  In 
another oncologic setting, liver metastasis, we can show that 
myeloid cells recruited to the liver colonies are induced to 
express FGF2 and that inhibition of FGF2 reduced the liver 
colony growth. These studies raise the possibility of FGF2 as 
a target for therapy in the setting of fractionated radiation 
therapy.  
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Purpose: Inhibition of the PI3K/mTOR pathway decreases 
hypoxia within SQ20B human head and neck cancer 
xenografts. We set out to understand the molecular 
mechanism underlying this observation. 
Experimental Design:  We measured oxygen consumption 
using both a Clark electrode and an extracellular flux 
analyzer. We made these measurements after various 
pharmacologic and genetic manipulations.   
Results: Pharmacologic inhibition of the PI3K/mTOR pathway 
or genetic inhibition of Akt/PI3K decreased the oxygen 
consumption rate (OCR) in vitro in SQ20B and other cell lines 
by 30-40%.  Pharmacologic inhibition of this pathway 
increased phosphorylation of the E1a subunit of the pyruvate 
dehydrogenase (PDH) complex on Ser293, which inhibits 
activity of this critical gatekeeper of mitochondrial 
respiration. Expressing wild type PTEN in a doxycycline-
inducible manner in a cell line with mutant PTEN led to an 
increase in PDH-E1a phosphorylation and a decrease in OCR. 
Pre-treatment of SQ20B cells with dichloroacetate (DCA), 
which inhibits PDH-E1a phosphorylation by inhibiting 
dehydrogenase kinases (PDKs), reversed the decrease in OCR 
in response to PI3K/Akt/mTOR inhibition. Likewise, 
introduction of exogenous PDH-E1a that contains serine to 
alanine mutations, which can no longer be regulated by 
phosphorylation, also blunted the decrease in OCR seen with 
PI3K/mTOR inhibition.  
Conclusions: Our findings highlight an association between 
the PI3K/mTOR pathway and tumor cell oxygen consumption 
that is regulated in part by PDH phosphorylation.  These 
results have important implications for understanding the 
effects PI3K pathway activation in tumor metabolism and also 
in designing cancer therapy trials that use inhibitors of this 
pathway.   
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Purpose/Objective: The anti-diabetic biguanides metformin 
(MET) and phenformin (PHEN) works by partial inhibition of 
respiration, and may have antineoplastic effects. Inhibition 
of respiration induces energetic stress and activation of the 
AMPK stress-signaling pathway possibly causing reduced 
tumor growth or cell death. Inhibition of respiration may also 
improve tumor oxygenation and thus radiosensitize tumors. 
Unfortunately, nearly all studies demonstrating anticancer 
effects of biguanides have used supraphysiological drug 
concentrations in vitro and ignored that cellular uptake 
depends on organic cation transporters (OCTs). The purpose 
of this study is to provide evidence for or against directly 
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mediated metabolic tumor effects using in vivo achievable 
biguanide concentrations. 
Materials and Methods: Initially we developed 11C labeled 
MET, which allowed assessment of in vitro cellular drug 
uptake and, importantly, in vivo biodistribution assessment 
using PET scans or organ dissection in tumor-bearing mice. 
Based on those results cellular effects of physiologically 
relevant doses of biguanides were tested in 14 cell lines using 
assays of proliferation/viability, glucose metabolism (FDG 
retention), respiration and lactic acid production 
(extracellular flux analyzer) and stress signaling. 
Finally, the two tumor models SiHa (cervix) and A549 (lung) 
were established in mice to assess acute and long-term 
metabolic, microenvironmental and anti-proliferative effects 
of PHEN treatment. 
Results: In vivo results showed that [MET] in blood peaked at 
250 μM in mice administered maximum tolerable dose (250 
mg/kg). Furthermore, MET was retained by tumor cells in 
vitro as well as in vivo, and uptake could be blocked by 
unlabeled MET suggesting involvement of OCTs. MET uptake 
varied widely among cell lines, with the highest uptake in 
A549. Likewise, inhibition of respiration and stimulation of 
glucose use and cell viability/proliferation was mostly 
affected in cell lines with high MET uptake. Even so, most 
cell lines were insensitive to in vivo achievable MET 
concentrations. PHEN was 100 times more potent than MET 
and induced profound metabolic changes at 50 μM in all cell 
lines, and down to a physiological relevant concentration of 1 
μM in A549. In accordance, PHEN was chosen for further 
testing in tumor-bearing mice. Data analysis of tumor 
microenvironment (hypoxia) and growth is ongoing.  
Conclusions: Biguanides affect cellular energy metabolism 
and proliferation in vitro but metabolic effects of MET were 
typically restricted to non-physiological concentrations and 
MET retention and sensitivity varied significantly among cell 
lines. PHEN exerted similar effects as MET but with greater 
potency and may affect a broader selection of tumors at 
physiologically achievable concentrations. Labeling of 
biguanides may allow PET-based identification of patients 
with treatment-responsive tumors. 
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Purpose/Objective: Carbon ions (12C-ions) show an increased 
relative biological effectiveness (RBE) relative to photons. To 
compare the impact of intra- and intertumor heterogeneity 
on the RBE, dose-response curves for photons and 12C-ions 
were determined for three sublines of a syngeneic rat 
prostate adenocarcinoma. 
Materials and Methods: Fresh tumor fragments from three 
sublines (AT1, HI and H) of the Dunning prostate tumor R3327 
were transplanted subcutaneously into the distal right thigh 
of male Copenhagen rats. Tumors were treated once with 
increasing single doses of either 12C-ions or 6 MeV photons. 
Primary endpoint was local tumor control within 300 days. 
For the H-tumor, histological tumor control, defined as 
absence of proliferation (BrdU-injection) in the remaining 
fibrotic nodules (Hematoxylin/Eosin staining) was used as 
secondary endpoint. RBE-values were calculated by the ratio 
of TCD50-values (dose to achieve 50% tumor control 
probability) for photons and 12C-ions, respectively. 
Results: Local tumor control can be achieved with 12C-ions 
and photons in all three sublines. For all tumors an increased 
effectiveness of 12C-ions was observed. The RBE for local 
tumor control increased from 1.62 ± 0.11 (H) to 2.08 ± 0.13 
(HI) to 2.30 ± 0.08 (AT1). Using histological tumor control, 
the RBE for the H-tumor increased to 1.80 ± 0.13. For 12C-ion 
irradiations the variation of TCD50-values between tumor 
sublines was significantly smaller than after photon 
irradiation. Additionally 12C-ion dose-response curves were 
much steeper compared to photons indicating a smaller 
intratumor heterogeneity for 12C-ions. 
Conclusions: The study confirms the increased relative 
biological effectiveness of 12C-ions in tumors, which is the 
highest for the highly radioresistant AT1-tumor and the 
smallest for the well-differentiated H-tumor. The very 
heterogeneous moderately differentiated HI-tumor lies in 
between. This indicates a clear correlation between 
decreasing differentiation status and increasing RBE. 12C-ions 
may therefore be beneficial especially in undifferentiated 
tumors, with a high photon resistance. Changes of RBE with 
tumor differentiation were predominantly caused by changes 
in the photon response. This supports the assumption that 
the response to 12C-ions is less dependent on tumor 
heterogeneity compared to photons. Thus heterogeneities 
within patient populations or the existence of radioresistant 
subpopulations within single tumors may be expected to have 
less impact on the 12C-ions radiation response. The underlying 
differential mechanisms are currently analyzed in ongoing 
histological and functional experiments.  
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